Uses of Cholinor: - High cholesterol Hyperlipidaemias, Homozygous familial sitosterolaemia, Hypercholesterolaemia Hypersensitivity; moderate to severe liver disease or unexplained serum transaminase elevation. Children <10 yr, lactation.

Ezetimibe

Ezetimibe localises at the brush border of the small intestine and inhibits absorption of cholesterol via the sterol transporter, Niemann-Pick C1-Like1 (NPC1L1). This results in decreased delivery of cholesterol to the liver, reduction of hepatic cholesterol stores and increased clearance of cholesterol from the blood.

How to use Ezetimibe: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Ezetimibe may be taken with or without food, but it is better to take it at a fixed time. Administration: May be taken with or without food. Adult Dose: Oral Hyperlipidaemias; Homozygous familial sitosterolaemia Adult: 10 mg once daily. Hepatic impairment Mild (Child-Pugh class A): Dose adjustment not necessary Moderate to severe (Child-Pugh class B or C): Not recommended Child Dose: Child: >10 yr: 10 mg once daily. Renal Dose: Renal impairment Monotherapy: No dosage adjustment required Moderate to severe: Renal impairment is a risk factor for statin-associated myopathy; caution when coadministered with doses of simvastatin exceeding 20 mg

Reduced absorption w/ colestyramine. Increased plasma concentrations w/ ciclosporin. Concomitant use w/ oral anticoagulants may result in increased INR.

Hypersensitivity; moderate to severe liver disease or unexplained serum transaminase elevation. Children <10 yr, lactation.

Common - Joint pain - Sinus inflammation - Diarrhea - Respiratory tract infection 1-10% Diarrhea (4%),Upper respiratory tract symptoms (2-4%),Cough (2-4%),Pain in extremity (3%),Sinusitis (3%),Arthralgia (2-3%),Fatigue (2%),Influenza (2%),Increased liver transaminases (with HMG-CoA reductase inhibitors; >3 x ULN; 1%)

There are no adequate and well-controlled studies of Ezetimibe in pregnant women. Ezetimibe should be used during pregnancy only if the potential benefit justifies the risk to the fetus

Precaution: Renal or mild hepatic impairment. Monitor LFTs. Immediately discontinue ezetimibe and any HMG-CoA reductase inhibitor or fibrate if myopathy is diagnosed or suspected. Exclude or treat secondary causes of dyslipidaemia prior to initiating therapy. Lactation: Excretion in milk unknown; use with caution

No cases of overdosage with Ezetimibe have been reported. Administration of Ezetimibe,50 mg/day, to 15 subjects for up to 14 days was generally well tolerated. In the event ofan overdose, symptomatic and supportive measures should be employed.

Store in a cool & dry place protected from light and moisture. Keep out of reach of children.

Ezetimibe

Ezetimibe localises at the brush border of the small intestine where it inhibits the absorption of cholesterol, thus decreasing its delivery to the liver. This results in decrease in cholesterol stores within the liver and an increase in cholesterol clearance from the blood.

Pregnancy category: C Lactation: Excretion in milk unknown; use with caution